Additional Proxy Soliciting Materials (definitive) (defa14a)
May 21 2021 - 04:11PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
SCHEDULE
14A
(Rule
14a-101)
INFORMATION
REQUIRED IN PROXY STATEMENT
SCHEDULE
14A INFORMATION
Proxy
Statement Pursuant to Section 14(a) of the Securities Exchange Act
of 1934
Filed
by the Registrant ☒
Filed
by a Party other than the Registrant ☐
Check
the appropriate box:
|
☐ |
Preliminary
Proxy Statement |
| ☐ |
Confidential,
for Use of the Commission Only (as permitted by Rule
14a-6(e)(2)) |
| ☐ |
Definitive
Proxy Statement |
| ☒ |
Definitive
Additional Materials |
| ☐ |
Soliciting
Material Pursuant to §240.14a-12 |
OncoCyte
Corporation
(Name
of Registrant as Specified in Its Charter)
(Name
of Person(s) Filing Proxy Statement if other than the
Registrant)
|
Payment
of Filing Fee (Check the appropriate box): |
|
☒ |
No
fee required. |
|
☐ |
Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11. |
|
|
(1) |
Title
of each class of securities to which transaction
applies: |
|
|
|
|
|
|
(2) |
Aggregate
number of securities to which transaction applies: |
|
|
|
|
|
|
(3) |
Per
unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which
the filing fee is calculated and state how it was
determined): |
|
|
|
|
|
|
(4) |
Proposed
maximum aggregate value of transaction: |
|
|
|
|
|
|
(5) |
Total
fee paid: |
|
|
|
|
|
☐ |
Fee
paid previously with preliminary materials. |
|
☐ |
Check
box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by
registration statement number, or the form or schedule and the date
of its filing. |
|
|
(1) |
Amount
previously paid: |
| |
|
|
| |
(2) |
Form,
schedule or registration statement no.: |
| |
|
|
| |
(3) |
Filing
party: |
| |
|
|
| |
(4) |
Date
filed: |
| |
|
|
 |
15
Cushing Road |
|
Irvine, CA 92618 |
| |
|
+844.ONCOCYTE |
|
+844.662.6298 |
|
+949.409.7600 |
| |
| customer.service@oncocyte.com |
| oncocyte.com |
May
21, 2021
Dear
Oncocyte Shareholder,
To
say 2020 was a fascinating year would be quite an understatement!
As I write, the United States is in full vaccination mode from the
worst pandemic in over a century and our way of life is slowly
returning to what will certainly be a “New Normal”. Despite the
macroenvironmental challenges of the past year, Oncocyte stayed
true to our mission and has entered 2021 much stronger than we
entered 2020!
2020
was a transformational year for our company with numerous
milestones achieved:
| |
● |
DetermaRx was launched in the spring as the pandemic started, and
despite the incredible headwind we encountered, we were able to
onboard 82 hospitals,138 treating physicians and identified over
100 patients who were high risk for recurring Non-Small Cell Lung
Cancer. |
| |
|
|
| |
● |
We acquired Insight Genetics in late January of 2020, and within 90
days we validated and launched DetermaIO™ into the pharma clinical
trial market as the only precision diagnostic available that can
predict which patients will have a sustained response to immune
therapy. In the past six months, our increased investments in
clinical studies have yielded numerous papers and abstracts that
have now validated DetermaIO in Non-Small Cell Lung Cancer (NSCLC),
Triple Negative Breast Cancer (TNBC) and Bladder Cancer, with more
on the way. We remain excited about the continued success of
DetermaIO and look forward to launching the test to the clinical
market in the second half of 2021 |
| |
|
|
| |
● |
In the Fall of 2020, we evaluated Chronix Biomedical’s IP and
technology, including TheraSure™ CNI, as a way to enter the
emerging $15B blood-based monitoring market for therapeutic
response and recurrence monitoring. Our diligence led to our
acquisition of Chronix in April. We expect Chronix’ CNI technology
and IP will be the foundation of our entry into this exciting and
very large market opportunity. We believe TheraSure™ CNI, which we
plan to re-brand as DetermaCNI™, will have clinical use in
monitoring a patient’s response to cancer treatment, including but
not limited to immunotherapy treatment. |
| |
|
|
| |
● |
Last April, following our acquisition of Insight Genetics, we
launched our Pharma Services from our newly acquired CLIA and CAP
certified lab in Nashville Tennessee, giving us an east coast
presence from which we are delivering a robust offering of
molecular laboratory services to pharma companies and diagnostic
platform providers. |
I am
extremely proud of our small but dedicated team and feel incredibly
fortunate to lead such an outstanding group of professionals! They
weathered the challenges of working through incredibly difficult
circumstances over the past year, and have met every milestone we
set for ourselves, on time. In only 6 quarters, we have
transitioned Oncocyte from a company with a single product focus to
an emerging leader in the world of oncology diagnostics with a
solid menu of novel tests. We have now accumulated the technologies
we need to execute on our vision of becoming the first choice of
physicians helping their patients make the major treatment
decisions confronting cancer patients each day.
We
appreciate the relentless support of our shareholders and
stakeholders! Without you we would not be in such a strong position
to fulfill our mission and deliver significant shareholder value
over the coming years. The future is incredibly bright, and we look
forward to sharing it with you.
Together
in the fight!
Ron
A. Andrews
OncoCyte (AMEX:OCX)
Historical Stock Chart
From May 2022 to Jun 2022
OncoCyte (AMEX:OCX)
Historical Stock Chart
From Jun 2021 to Jun 2022
